Cyclin-dependent kinase inhibitors: a survey of recent patent literature

Bibliography

• Manning G, Whyte DB, Martinez R, The protein kinase complement of the human genome. Science 2002;298:1933-34
   Web of Science ®Google Scholar
• Niedner RH, Buzko OV, Haste NM, Protein kinase resource: an integrated environment for phosphorylation research. Proteins 2006;63:78-86
   PubMed Web of Science ®Google Scholar
• Bloom J, Cross FR. Multiple levels of cyclin specificity in cell-cycle control. Nat Rev Mol Cell Biol 2007;8:149-60
   PubMed Web of Science ®Google Scholar
• Kennedy H, Dehay C. Cell-cycle control and cortical development. Nat Rev Neurosci 2007;8:438-50
   PubMed Web of Science ®Google Scholar
• Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002;23:417-25
   PubMed Web of Science ®Google Scholar
• Obligado SH, Ibraghimov-Beskrovnaya O, Zuk A, CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases. Kidney Int 2008;73:684-90
   PubMed Web of Science ®Google Scholar
• Rossi AG, Sawatzky DA, Walker A. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 2006;12:1056-64
   PubMed Web of Science ®Google Scholar
• Schang L. Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs. Curr Drug Targets Infect Disord 2005;5:29-37
   PubMedGoogle Scholar
• Koedel U, Frankenberg T, Kirschnek S, Apoptosis is essential for neutrophil functional shutdown and determines tissue damage in experimental pneumococcal meningitis. PLoS Pathog 2009;5:e1000461
   PubMed Web of Science ®Google Scholar
• Baumli S, Lolli G, Lowe ED, The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J 2008;27:1907-18
   PubMed Web of Science ®Google Scholar
• Utreras E, Maccioni R, González-Billault C. Cyclin-dependent kinase 5 activator p35 over-expression and amyloid beta synergism increase apoptosis in cultured neuronal cells. Neuroscience 2009;161:978-87
   Google Scholar
• Hou T, Ray S, Brasier AR. The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression. J Biol Chem 2007;282:37091-102
   PubMedGoogle Scholar
• Wang S, Fischer PM. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci 2008;29:302-13
   PubMed Web of Science ®Google Scholar
• Sharma PS, Sharma R, Tyagi R. Inhibitors of cyclin dependent kinases: useful targets for cancer treatment. Curr Cancer Drug Targets 2008;8:53-75
   PubMed Web of Science ®Google Scholar
• Meijer L, Bettayeb K, Galons H. Roscovitine (CYC202, seliciclib). CDK inhibitors and their potential as anti-tumor agents. In: Yue E, Smith PJ, editors, Chapter 9, Monographs on enzyme inhibitors. (Volume 2). Taylor & Francis, CRC Press; 2006. p. 187-226
   Google Scholar
• Christian BA, Grever MR, Byrd JC, Flavopiridol in the treatment of chronic lymphocytic leukemia. Curr Opin Oncol 2007;19:573-8
   PubMed Web of Science ®Google Scholar
• Malumbres M, Pevarello P, Barbacid M, CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2008;29:16-21
   PubMed Web of Science ®Google Scholar
• Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 2009;16:36-43
   PubMed Web of Science ®Google Scholar
• Benson C, White J, De Bono J, A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007;96:29-37
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Lacy MQ, Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. Haematologica 2006;9:390-3
   Google Scholar
• Fornier MN, Rathkopf D, Shah M, Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007;13:5841-6
   PubMed Web of Science ®Google Scholar
• Karp JE, Smith BD, Levis MJ, Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res 2007;13(15 Pt 1):4467-73
   PubMed Web of Science ®Google Scholar
• Heath EI, Bible K, Martell RE, A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 2008;26:59-65
   Google Scholar
• Graham JS, Plummer R, McCoy C, Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery). Eur J Cancer 2008;44:2162-8
   PubMed Web of Science ®Google Scholar
• Shapiro GI, Bannerji R, Small K, A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies. J Clin Oncol (Meeting Abstracts) 2008;26:3532
   Web of Science ®Google Scholar
• Nemunaitis J, Saltzman M, Rosenberg MA, A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SCH 727965, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Clin Oncol (Meeting Abstracts) 2009;27:3535
   Web of Science ®Google Scholar
• Diab S, Eckhardt A, Tan G, A phase I study of R547, a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs). ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2007;25:18S;3528
   Google Scholar
• Agouron. 3,5-Disubstituted indazole compounds. Pharmaceutical compositions, or method for mediating or inhibiting cell proliferation. US0142345; 2006
   Google Scholar
• Agouron. Pyrrole substituted 2-indolinone protein kinase inhibitors. US7125905; 2006
   Google Scholar
• Astex. 1H - indazole - 3 - carboxamide compounds as MAPKAP kinase modulators and their preparation. WO014607; 2005
   Google Scholar
• Astex. Preparation of thiazole and isothiazole derivatives that modulate the activity of CDK, GSK and aurora kinases. WO070192; 2006
   Google Scholar
• Astex. Pharmaceutical compounds such as substituted thiazole and isothiazole derivatives and their preparation, pharmaceutical compositions, formulations, and use in prophylaxis or treatment of disease states or conditions mediated by cyclin dependent kinase such as cancers, fungal infections or agricultural use. WO008545; 2006
   Google Scholar
• Astex. Preparation of 3, 4 - disubstituted 1h - pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators. WO012256; 2005
   Google Scholar
• Squires MS, Feltell RE, Wallis NG, Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther 2009;8:324-32
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Plummer R, Squires MS, A dose escalation, pharmacokinetic, and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. J Clin Oncol (Meeting Abstracts) 2008;26:3533
   Web of Science ®Google Scholar
• Astex. Pharmaceutical compounds. WO077426; 2006
   Google Scholar
• Astex. Medicaluse of cyclin dependent kinase inhibitors. WO009954; 2008
   Google Scholar
• Shaha, S, Chan D, Tear S. Licensing highlights. IDrugs 2006;9:139-44
   Google Scholar
• Astex. Preparation of 3, 4 - disubstituted pyrazoles as inhibitors of cyclin dependent kinases (CDK), Aurora A kinase or glycogen synthase kinase 3 (GSK3). WO003440; 2006
   Google Scholar
• Astex. 3-Benzoylamino-1H-pyrazole-4- carboxamides as CDK kinase inhibitors, and their preparation, pharmaceutical combinations and use in the treatment of proliferative diseases. WO007122; 2008
   Google Scholar
• Wyatt PG, Woodhead AJ, Berdini V, Identification of N-(4-piperidinyl)-4- (2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J Med Chem 2008;51:4986-99
   PubMed Web of Science ®Google Scholar
• Astex. Benzimidazoles derivatives and their use as protein kinases inhibitors. WO002552; 2005
   Google Scholar
• Astex. Preparation of benzimidazolylpyrazole compounds that modulate the activity of cdk, gsk and aurora kinasis. WO070195; 2006
   Google Scholar
• Howard S, Berdini V, Boulstridge JA, Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 2009;52:379-88
   PubMed Web of Science ®Google Scholar
• Astex. Preparation of pyrazole derivatives that modulate the activity of CDK, GSK and aurora kinases. WO070198; 2006
   Google Scholar
• Astex. Pyrazole derivatives having kinase modulating activity. WO070202; 2006
   Google Scholar
• Astex. Preparation of substituted pyrazoles as cyclin dependent kinase inhibitors. WO007123; 2008
   Google Scholar
• AstraZeneca. Preparation of 4-(4-(imidazol-4-yl)-pyrimidin- 2-ylamino)benzamides as CDK inhibitors. WO064251 2006
   Google Scholar
• AstraZeneca. 2 Preparation of 2-anilinopyrimidines as cyclin dependent kinase inhibitors. WO0096887; 2002
   Google Scholar
• Boss DS, Schwartz GK, Middleton MR, Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. Ann Oncol Access, published online on 13 October 2009
   Google Scholar
• Jones CD, Andrews DM, Barker AJ, Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett 2008;18:6486-9
   PubMed Web of Science ®Google Scholar
• Jones CD, Andrews DM, Barker AJ, The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing. Bioorg Med Chem Lett 2008;18:6369-73
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. Preparation of alpha-carbolines as CDK1 inhibitors. WO131552; 2006
   Google Scholar
• Cyclacel. Use of 2-substituted-4-heteroarylpyrimidines that are protein kinase inhibitors for treating a variety of disorders. WO042786; 2007
   Google Scholar
• Hsieh WS, Soo R, Peh BK, Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin Cancer Res 2009;15:1435-42
   PubMed Web of Science ®Google Scholar
• Yeo W, Goh B, Le Tourneau C, A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma [abstract 6026]. J Clin Oncol 2009;27(Suppl):15s
   Google Scholar
• Cyclacel. Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders. WO122779; 2008
   Google Scholar
• Cyclacel. Histone deacetylase inhibitor combination with purine derivative or pyrimidine derivative for proliferative disorder treatment. WO054725; 2007
   Google Scholar
• Cyclacel. Combination comprising CNDAC (2′-cyano-2′-deoxy-N4-palmitoyl-1-beta−D-arabinofuranosyl-cytosine) and a cytotoxic agent for the treatment of proliferative disorders. WO075042; 2008
   Google Scholar
• Cyclacel. Combination comprising a CDK inhibitor and cisplatin. US0276866; 2005
   Google Scholar
• Cyclacel. Pharmaceutical composition comprising a CDK inhibitor and gemcitabine. US267066; 2005
   Google Scholar
• Cyclacel. Combination of a CDK inhibitor and mitoxantrone. US261260; 2005
   Google Scholar
• Cyclacel. Combination comprising a CDK inhibitor and a topoisomerase I inhibitor for the treatment of cancer and other proliferative diseases. US148828; 2006
   Google Scholar
• Cyclacel. Combination comprising docetaxel and a CDK inhibitor. US0277656; 2005
   Google Scholar
• Cyclacel. Combination comprising a cyclin-dependent kinase (CDK) inhibitor and doxorubicin for use in the treatment of proliferative disorders. US0222054; 2005
   Google Scholar
• Cyclacel. Method of treatment and compositions for a disease associated with antinuclear antibodies. WO021803; 2006
   Google Scholar
• Gilead. Imidazopyridinyl thiazolyl compounds as histone deacetylase inhibitors and their preparation and use in the treatment of diseases. WO002534; 2009
   Google Scholar
• Gpc Biotech. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto. WO063765; 2005
   Google Scholar
• Gpc Biotech. Pyrazolopyrimidinone derivative as cyclin dependent kinase inhibitor and its preparation, pharmaceutical compositions and use in the treatment of cancer. WO145678; 2008
   Google Scholar
• Hoffmann-La Roche. Preparation of thiazolinone 4-monosubstituted quinolines as CDK1-Cyclin B inhibitors for use as anti-cancer agents. WO029861; 2006
   Google Scholar
• Hoffmann-La Roche. Thiazolinone 3,4-disubstituted quinolines as CDK1 inhibitors for treating cancer. WO002828; 2006
   Google Scholar
• Hoffmann-La Roche. Preparation of substituted 1,5-naphthyridine azolinones. Available from: http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale= fr_fr&FT=D&date=20061012&CC= WO&NR=2006106046A1&KC=A1 WO106046; 2006
   Google Scholar
• Hoffmann-La Roche. Preparation of novel 2,4-diamino-5-benzoylthiazoles as inhibitors of cyclin-dependent kinases for treating cancer. WO005508; 2006
   Google Scholar
• Hoffmann-La Roche. Preparation of 4-aminopyrimidine-5-thione derivatives as cyclin-dependent kinase inhibitors for treating proliferative disorders. WO060110; 2007
   Google Scholar
• DePinto W, Chu XJ, Yin X, In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther 2006;5:2644-58
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche. Preparation of pyrazolopyrimidines as antitumor agents. WO121107; 2005
   Google Scholar
• Hoffmann-La Roche. Preparation of novel 2,6-diaminopyridin-3-yl phenyl methanones as inhibitors of cyclin-dependent kinases for treating cancer. WO005548; 2006
   Google Scholar
• Hoffmann-La Roche. Preparation of aminopyrimidinylbenzotriazoles as kinase modulators. WO028860; 2008
   Google Scholar
• Ingenium. Cyclin-dependent kinase (CDK) inhibitors for treating pain. WO065155; 2008
   Google Scholar
• Ingenium. 4,6-Disubstituted aminopyrimidine derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO132138; 2008
   Google Scholar
• Genzyme. Purine derivatives for the treatment of cystic diseases. WO051502; 2008
   Google Scholar
• Bukanov NO, Smith LA, Klinger KW, Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 2006;444:949-52
   PubMed Web of Science ®Google Scholar
• Janssen. A preparation of diaminopyridine derivatives, useful as cyclin-dependent kinase (CDK) inhibitors. WO051387; 2005
   Google Scholar
• Janssen. Preparation of triazolopyrimidine derivatives as serine-tyrosine and tyrosine kinases inhibitors. WO076442; 2006
   Google Scholar
• Nerviano. Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic. WO090794; 2007
   Google Scholar
• Nerviano. Preparation of pyrazoloquinazolines as inhibitors of protein kinases such as aurora2 for the treatment of proliferative disorders such as cancer, alzheimer's disease, and autoimmune diseases. US557565; 2006
   Google Scholar
• Nerviano. Preparation of substituted pyrrolopyrazole derivatives as protein kinase inhibitors, particularly PLK-1 kinase, for treating proliferative disorders such as cancer. WO043745; 2008
   Google Scholar
• Nerviano. Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors. WO074788; 2008
   Google Scholar
• Novartis. Preparation of 2,6-naphthyridines as AGC protein kinase modulators. WO122614; 2008
   Google Scholar
• Novartis. Preparation of pyridinyl-substituted pyrimidine derivatives as inhibitors of cyclin-dependently kinase (CDK). WO079933; 2008
   Google Scholar
• Novartis. Preparation of (indol-4-yl)pyrimidin-2-ylamine derivatives as cyclin-dependent kinase inhibitors. WO079918; 2008
   Google Scholar
• Pfizer. Combinations of signal transduction inhibitors. WO0094830; 2005
   Google Scholar
• Panacea. Methods of neuroprotection by cyclin-dependent kinase inhibition. WO076946; 2008
   Google Scholar
• Schering. Preparation of pyrazolotriazines as kinase inhibitors for treating cancer and other diseases associated with a kinase. WO082908; 2005
   Google Scholar
• Schering. Pyrazolo[1,5-a]pyrimidines as CDK inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO139732; 2007
   Google Scholar
• Schering. A process for preparing amino-substituted pyrazolo[1,5-a]pyrimidine derivatives and their intermediates. WO027220; 2008
   Google Scholar
• Schering. Preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors. WO045267; 2008
   Google Scholar
• Schering. Preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors. WO045266; 2008
   Google Scholar
• Schering. Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors. WO044449; 2007
   Google Scholar
• Schering. Preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors. WO045268; 2008
   Google Scholar
• Schering. Imidazopyrazines as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of kinase-mediated diseases. WO145921; 2007
   Google Scholar
• Schering. Imidazopyrazines as protein kinase inhibitors and their preparation and use in the treatment of kinase-mediated diseases. WO156614; 2008
   Google Scholar
• Schering. Novel 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2H-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines compounds as cyclin dependent kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO032936; 2007
   Google Scholar
• Schering. 2-Aminothiazole-4-carboxylic amides as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO054749; 2008
   Google Scholar
• Schering. 2-Aminothiazole-4-carboxylic acid amides as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO054701; 2008
   Google Scholar
• Schering. Novel high affinity thiophene-based and furan-based kinase ligands and their preparation, pharmaceutical compositions and use in the treatment of CDK-2 mediated diseases. WO022258; 2007
   Google Scholar
• Schering. Novel high affinity quinoline-based kinase ligands and their preparation, pharmaceutical compositions and use in the treatment and prevention of diseases. WO022241; 2007
   Google Scholar
• Schering. Sulfoximine-substituted pyrimidines as kinase inhibitors, their preparation and use as drugs. WO071455; 2007
   Google Scholar
• Schering. Preparation of benzenacyclononaphanes as aurora kinase inhibitors. WO079982; 2007
   Google Scholar
• Schering. A-G. N-Arylsulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors and their production and use as pharmaceutical agents. WO099974; 2006
   Google Scholar
• Aventis Pharma. New benzothiazoles, their preparation and use as Aurora 2 and CDK2 kinase inhibitors for treating neoplasm. WO097787; 2005
   Google Scholar
• Aventis Pharma. Method of preparation of novel purine derivatives and their use as antifungal medicines. US0090849; 2008
   Google Scholar
• Aventis Pharma. Preparation of novel pyridazinone derivatives as inhibitors of CDK2. US0259870; 2007
   Google Scholar
• Senex. CDKI pathway inhibitors as selective inhibitors of tumor cell growth. WO133772; 2007
   Google Scholar
• Warner-Lambert. Preparation of 2-(pyridin-3-ylamino)pyrido[2,3-d]pyrimidin-7-ones as inhibitors of cyclin-dependent kinases 2 and 4. WO082903; 2005
   Google Scholar
• Nicholas Piramal. Enantiomerically pure flavone derivatives for the treatment of proliferative disorders and processes for their preparation. WO148158; 2007
   Google Scholar
• Nicholas Piramal. An enantioselective synthesis of pyrrolidine-substituted flavones. WO007169; 2008
   Google Scholar
• Raje N, Hideshima T, Mukherjee S, Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 2009;23:961-70
   PubMed Web of Science ®Google Scholar
• Hirte HW, Raghunadharao, D, Baetz T, Phase 1 study of the selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms. J Clin Oncol (Meeting Abstracts) 2007;25:14117
   Web of Science ®Google Scholar
• Piramal. A synergistic pharmaceutical combination for the treatment of cancer. WO139271; 2008
   Google Scholar
• Cephalon. Preparation of substituted pyrazolopyrimidines as inhibitors of glycogen synthase kinase 3 and cyclin dependent kinase 5. WO063232; 2008
   Google Scholar
• Alcon. Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies. US0176964; 2008
   Google Scholar
• Axxima Pharmaceuticals AG. Preparation of pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases. WO026129; 2005
   Google Scholar
• Genentech. Cdk2 inhibitors. WO0105386; 2006
   Google Scholar
• Castanedo G, Kevin Clark K, Shumei Wang S, CDK2/cyclinA inhibitors: Targeting the cyclinA recruitment site with small molecules derived from peptide leads. Bioorg Med Chem Lett 2006;16:1716-20
   PubMed Web of Science ®Google Scholar
• CNRS. Synthesis of pyrrolo[2,3-b]pyridine compounds, azaindole compounds used in the synthesis of these compounds, their fabrication processes, and their uses. WO129152; 2008
   Google Scholar
• Echalier A, Bettayeb K, Ferandin Y, Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. J Med Chem 2007;51:737-51
   Web of Science ®Google Scholar
• Bettayeb K, Tirado OM, Marionneau-Lambot S, Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res 2007;67:8325-34
   PubMed Web of Science ®Google Scholar
• Emory University. Pyrazolopyrimidinamine compounds as selective inhibitors for cyclin-dependent kinases and their preparation, pharmaceutical compositions and use in the treatment of CDK-mediated diseases. WO151304; 2008
   Google Scholar
• Ali S, Heathcote DA, Kroll SH, The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res 2009;69:6208-15
   PubMed Web of Science ®Google Scholar
• Institute of Experimental Botany. 4-Arylazo-3,5-diaminopyrazole compounds and their preparation, pharmaceutical compositions, inhibition of cyclin-dependent kinases and treatment of proliferative and viral disorders. WO024858; 2006
   Google Scholar
• Krystof V, Cankar P, Frysová I, 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem 2006;49:6500-9
   PubMed Web of Science ®Google Scholar
• Fundacion de La Comunidad Valenciana. Cyclin A/kinase 2 complex inhibitors targeting new pharmacophoric site for treatment of cancer. WO000870; 2008
   Google Scholar
• The Rockefeller University. Indirubin-type compounds, compositions, and methods for their use. WO041954; 2005
   Google Scholar
• Myrianthopoulos V, Magiatis P, Ferandin Y, An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins. J Med Chem 2007;50:4027-37
   PubMed Web of Science ®Google Scholar
• Johnson LN. The regulation of protein phosphorylation. Biochem Soc Trans 2009;(Pt 4):627-41
   PubMed Web of Science ®Google Scholar
• Strock CJ, Park JI, Nakakura EK, Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res 2006;66:7509-15
   Google Scholar
• Kodym E, Kodym R, Reis AE, The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells. Lung Cancer 2009. In press
   PubMed Web of Science ®Google Scholar
• De Azevedo WF Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 1996;93:2735-40
   PubMed Web of Science ®Google Scholar
• De Azevedo WF, Leclerc S, Meijer L, Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 1997;243:518-26
   PubMedGoogle Scholar
• Lu H, Chang DJ, Baratte B, Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. J Med Chem 2005;48:737-43
   PubMed Web of Science ®Google Scholar
• Fischmann TO, Hruza A, Duca JS, Structure-guided discovery of cyclin-dependent kinase inhibitors. Biopolymers 2008;89:372-9
   PubMed Web of Science ®Google Scholar
• Xiang J, Yang H, Che C, Identifying tumor cell growth inhibitors by combinatorial chemistry and zebrafish assays. PLoS ONE 2009;4:e4361
   Web of Science ®Google Scholar
• Murray CW, Rees DC. The rise of fragment based drug discovery. Nat Chem 2009;1:187-92
   PubMed Web of Science ®Google Scholar
• Goldstein DM, Gray NS, Zarrinkar PP. High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug Discov 2008;7:391-7
   PubMed Web of Science ®Google Scholar
• Bach S, Knockaert M, Reinhardt J, Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 2005;280:31208-19
   PubMed Web of Science ®Google Scholar
• Missner E, Bahr I, Badock V, Off-target decoding of a multitarget kinase inhibitor by chemical proteomics. Chembiochem 2009;10:1163-74
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66
   PubMed Web of Science ®Google Scholar
• Hunt T. You never know: Cdk inhibitors as anti-cancer drugs. Hunt T. Cell Cycle 2008;7:3789-90
   PubMed Web of Science ®Google Scholar
• Ganapathi SB, Kester M, Elmslie KS. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy. Am J Physiol Cell Physiol 2009;296:C701-10
   Google Scholar
• Tirado OM, Mateo-Lozano S, Notario V. Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo. Cancer Res 2005;65:9320-7
   PubMed Web of Science ®Google Scholar
• Kitani K, Oguma S, Nishiki T, A Cdk5 inhibitor enhances the induction of insulin secretion by exendin-4 both in vitro and in vivo. J Physiol Sci 2007;57:235-9
   PubMed Web of Science ®Google Scholar